Fig. 1
From: MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer’s disease
Study design for the 4-week pharmacological MMP9 inhibition and MMP9 gene deletion in vivo analysis. A Study 1. MMP9 was pharmacologically inhibited in E4FAD mice through a 4-week treatment with vehicle or SB-3CT (25 mg/kg), injected intraperitoneally (IP). B Study 2. MMP9KO mice were crossed with 5xFAD mice to create 5xFAD/MMP9KO mice, which were tested alongside WT, 5xFAD and MMP9KO mice. Behavioral analysis consisted of the elevated plus maze (EPM), open field test (OFT), three chamber test and the radial arm water maze (RAWM). MMP Matrix metallopeptidase, E4FAD Apolipoprotein E4 x Familial Alzheimer’s disease, MMP9KO MMP9 knockout, WT Wild-type